| Document |
Document Title |
|
WO/2023/113575A1 |
The present specification relates to a compound of Formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/114198A2 |
The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof. The methods involve subjecting an intermediate in the synthesis of a complement factor D inhibitor to a t-butyl ester ...
|
|
WO/2023/110473A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/114733A1 |
Provided herein are KRAS modulating compounds, such as compounds of Formula (I) and various Sub Formulas or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modul...
|
|
WO/2023/114061A1 |
The present invention provides a crystalline compound of the formula : wherein the crystalline compound is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and psoriasis.
|
|
WO/2023/109004A1 |
A naphthylurea-piperazine compound, a preparation method therefor and a use thereof. The compound can significantly inhibit the activation of JAKs/STATs signaling at a low dose. The results of cell proliferation experiments, western blot...
|
|
WO/2023/109745A1 |
Provided are a compound of general formula I capable of specifically binding to an α-synuclein aggregate, a radiolabeled compound thereof, a preparation method therefor, and a use thereof. The compound can be used as a small-molecule pr...
|
|
WO/2023/113576A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/110871A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2023/110710A1 |
A method for combating and controlling diamide-resistant insects to(i) reduce damage on a plant, which comprises applying to the insect, to a locus of the insect, or to a plant susceptible to attack by the insect, an effective amount of ...
|
|
WO/2023/113577A1 |
The present specification relates to compounds of chemical formula 1 and chemical formula 2 and an organic light-emitting device comprising same.
|
|
WO/2023/110138A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/114365A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2023/111181A1 |
The present invention relates to a compound according to formula (I), and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical composition...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/107145A1 |
The present disclosure relates generally to methods for treating cancer, in particular hematologic cancers, with an N-(1H-imidazol-2-yl)benzamide compound of a salt thereof, optionally in combination with a PARP inhibitor or a BTK inhibi...
|
|
WO/2023/107979A1 |
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
|
|
WO/2023/104170A1 |
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) can be used to treat polyQ-related neurode...
|
|
WO/2023/107722A1 |
This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
|
|
WO/2023/107660A1 |
The present disclosure encompasses a solid-state form of Lotilaner, in embodiment processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure further encompasses Lotilaner salts and their solid stat...
|
|
WO/2023/104564A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/107863A1 |
Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.
|
|
WO/2023/107714A2 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
|
|
WO/2023/105387A1 |
Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such com...
|
|
WO/2023/102653A1 |
Provided herein are compounds that inhibit glycogen synthase kinase-3 (GSK3) giving them antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (I) and (II), for use as antiviral agents ...
|
|
WO/2023/104155A1 |
The present disclosure relates to compounds of formula (I) and formula (II), or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs of said compounds, and the uses of same. The present discl...
|
|
WO/2023/106310A1 |
The present invention pertains to: a compound, or a pharmacologically acceptable salt thereof, having GLP-1 receptor agonist activity and offering utility as an agent for treating or preventing diseases involving GLP-1 receptors; and a p...
|
|
WO/2023/106625A1 |
The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/103850A1 |
Provided are a small molecule STING agonist, a preparation method therefor, and an application. Specifically, the present invention provides the compound represented by structural formula I, the compound having STING agonist activity. Th...
|
|
WO/2023/104882A1 |
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2023/102184A1 |
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
|
WO/2023/102022A1 |
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and phar...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/099445A1 |
The present invention relates to Bis(hetero)aryl thioether oxadiazine derivatives and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for prepa...
|
|
WO/2023/099425A1 |
The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and sho...
|
|
WO/2023/098815A1 |
An aromatic compound, a pharmaceutical composition, and an application thereof. Specifically disclosed are the compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptabl...
|
|
WO/2023/099592A1 |
The present invention encompasses compounds of formula (V), wherein R1a, R1b, R2a, R2b, Z, R4, R5, R14, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical composition...
|
|
WO/2023/099561A1 |
The present invention relates to a class of substituted N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial ...
|
|
WO/2023/098699A1 |
The present invention provides compounds of Formula (I) which can be used as CD38 inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as...
|
|
WO/2023/101326A1 |
The present invention relates to a compound that is an autotaxin (ATX) inhibitor. More specifically, the present invention relates to a novel compound having an inhibitory effect on autotaxin activity, a pharmaceutical composition compri...
|
|
WO/2023/098656A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparatio...
|
|
WO/2023/097678A1 |
A method for synthesizing (R)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2
-one. The synthesis route of the method is: where X is Br, Cl or I, preferably Br. Preferably, chiral phenyloxazolidin-2-one is prepared from a 2-brom...
|
|
WO/2023/102231A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...
|
|
WO/2023/099620A1 |
The present invention relates to compounds and derivatives of formula (I) which target KRAS and can be useful as agents for treatment and/or prevention of oncological diseases.
|
|
WO/2023/097194A2 |
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2023/096850A1 |
The invention provides novel phosphoinositide 3 kinase gamma-selective inhibitors and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as solid tumo...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/092195A1 |
Analogues of 3,4-methylenedioxymethamphetamine (MDMA), processes for their preparation, medicaments and medical methods of treatment comprising said MDMA analogues, and medical uses of said MDMA analogues. The MDMA analogues are capable ...
|
|
WO/2023/095167A1 |
The present disclosure relates to a new, simple, two step synthesis of Indolmycin and its derivatives of formula (I), in 4-5 hours. Formula (I) wherein said process comprising the step of: 10 (a) reacting indole derivative with methyl ma...
|
|
WO/2023/097031A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
